ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS W/ LUNG CANCER

对 MUC 1 阳性肺癌患者进行抗原特异性免疫治疗

• 批准号: 6265347
• 负责人: BARBARA J GITLITZ
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265347
• 关键词: clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; interleukin 2; lung neoplasms; mucins; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; vaccinia virus; vector vaccine

TG 1031, an attenuated recombinant vaccinia virus containing sequences coding for the human MUC-1, and Interleukin 2 (IL-2) genes, has been designed for use in human clinical applications, especially in oncology. The vector, vaccinia virus, has been used extensively to vaccinate against smallpox and the virus is known to be highly immunogenic. The second component of the product, MUC1, is a mucin producing gene which is pre-expressed in a variety of adenocarcinomas.

TG 1031是一种减毒重组牛痘病毒，含有编码人MUC-1和白细胞介素2（IL-2）基因的序列，已被设计用于人临床应用，特别是肿瘤学。载体牛痘病毒已广泛用于接种天花疫苗，并且已知该病毒具有高度免疫原性。 该产物的第二组分MUC 1是一种产生粘蛋白的基因，其在多种腺癌中预表达。